Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q9)Sep 30, 2025 | (Q6)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 2.23%137.67B | 1.77%86.29B | -2.68%43.41B | 8.94%174.22B | 12.70%134.66B | 18.04%84.79B | 30.97%44.6B | 83.70%159.93B | 70.31%119.49B | 75.98%71.83B |
| Operating income | 2.23%137.67B | 1.77%86.29B | -2.68%43.41B | 8.94%174.22B | 12.70%134.66B | 18.04%84.79B | 30.97%44.6B | 83.70%159.93B | 70.31%119.49B | 75.98%71.83B |
| Cost of sales | ---- | 1.47%-40.66B | ---- | -8.13%-83.05B | ---- | -20.01%-41.27B | ---- | -49.88%-76.8B | ---- | -47.99%-34.39B |
| Operating expenses | -0.68%-121.56B | 1.47%-40.66B | 0.00%-39.73B | -8.13%-83.05B | -13.52%-120.74B | -20.01%-41.27B | -19.32%-39.73B | -49.88%-76.8B | -32.59%-106.36B | -47.99%-34.39B |
| Gross profit | 15.66%16.1B | 4.85%45.63B | -24.49%3.68B | 9.68%91.18B | 6.00%13.92B | 16.23%43.52B | 540.74%4.88B | 132.09%83.13B | 230.63%13.14B | 112.97%37.44B |
| Selling expenses | -7.00%-5.54B | -5.60%-3.36B | -11.12%-1.8B | -7.59%-6.83B | -7.97%-5.17B | -10.69%-3.18B | -21.75%-1.62B | -45.79%-6.35B | -59.91%-4.79B | -59.73%-2.87B |
| Administrative expenses | -4.11%-3.14B | -2.96%-2.13B | -7.69%-1.08B | -6.87%-4.44B | -9.99%-3.02B | -7.39%-2.06B | -14.79%-1B | -18.20%-4.15B | -11.77%-2.74B | -20.20%-1.92B |
| Research and development expenses | -4.47%-397M | ---- | -19.40%-160M | ---- | -0.80%-380M | ---- | -17.54%-134M | ---- | -40.67%-377M | ---- |
| Profit from asset sales | -80.42%65M | ---- | -82.28%14M | ---- | 33.33%332M | ---- | -50.63%79M | ---- | 67.11%249M | ---- |
| Depreciation and amortization | ---- | -7.16%-14.93B | ---- | -4.33%-28.34B | ---- | -7.22%-13.94B | ---- | -11.95%-27.17B | ---- | -9.61%-13B |
| Revaluation surplus | 89.55%381M | ---- | 464.38%412M | ---- | -64.98%201M | ---- | 247.62%73M | ---- | 250.00%574M | ---- |
| -Changes in the fair value of other assets | 89.55%381M | ---- | 464.38%412M | ---- | -64.98%201M | ---- | 247.62%73M | ---- | 250.00%574M | ---- |
| Impairment and provision | 50.00%3M | ---- | ---- | 145.53%302M | 128.57%2M | --304M | ---- | 127.39%123M | -123.33%-7M | ---- |
| -Impairment of property, machinery and equipment | ---- | ---- | ---- | ---- | ---- | --304M | ---- | ---- | ---- | ---- |
| -Other impairment is provision | 50.00%3M | ---- | ---- | 145.53%302M | 128.57%2M | ---- | ---- | 127.39%123M | -123.33%-7M | ---- |
| Special items of operating profit | 58.41%2.51B | -8.70%-21.89B | -64.62%323M | -8.78%-43.55B | -51.78%1.59B | -10.54%-20.14B | 5.43%913M | -55.29%-40.03B | 11.30%3.29B | -41.32%-18.22B |
| Adjustment items of operating profit | -50.00%-6M | ---- | ---- | ---- | ---4M | ---- | ---- | ---- | ---- | ---- |
| Operating profit | 36.24%9.56B | -26.27%3.32B | -58.93%1.26B | 49.85%8.33B | -21.66%7.02B | 214.52%4.51B | 570.46%3.06B | 124.65%5.56B | 170.72%8.96B | 113.56%1.43B |
| Financing income | ---- | 45.26%138M | ---- | -40.44%215M | ---- | -56.62%95M | ---- | -21.01%361M | ---- | -12.40%219M |
| Financing cost | 5.46%-4.05B | 4.05%-2.79B | 13.91%-1.33B | 2.87%-5.76B | 19.34%-4.29B | 2.02%-2.91B | -88.37%-1.54B | 1.30%-5.93B | 37.24%-5.32B | 0.64%-2.97B |
| Share of profits of associates | ---- | 35.30%-854M | ---- | 44.56%-1.24B | ---- | -7,433.33%-1.32B | ---- | -17,161.54%-2.24B | ---- | 200.00%18M |
| Share of profit from joint venture company | ---- | 84.04%519M | ---- | 15.02%628M | ---- | 1.08%282M | ---- | 79.61%546M | ---- | 86.00%279M |
| Special items of earning before tax | ---- | 187.54%260M | ---- | -483.42%-717M | ---- | 60.03%-297M | ---- | 104.99%187M | ---- | 62.53%-743M |
| Adjustment items of earning before tax | -73.74%584M | ---- | 59.38%102M | ---- | 590.68%2.22B | ---- | 0.00%64M | ---- | -39.36%322M | ---- |
| Earning before tax | 22.97%6.09B | 66.39%594M | -97.92%33M | 195.40%1.45B | 24.94%4.96B | 120.24%357M | 212.83%1.58B | 95.18%-1.52B | 119.24%3.97B | 88.34%-1.76B |
| Tax | -65.12%-2.1B | -86.54%-1.43B | -22.94%-402M | 0.70%-1.43B | -6.19%-1.27B | -6.69%-765M | -1.87%-327M | 33.70%-1.44B | -148.34%-1.2B | -122.81%-717M |
| After-tax profit from continuing operations | 8.44%4B | -104.17%-833M | -129.38%-369M | 100.85%25M | 33.03%3.69B | 83.56%-408M | 172.85%1.26B | 91.23%-2.96B | 115.27%2.77B | 79.30%-2.48B |
| Earning after tax | 8.44%4B | -104.17%-833M | -129.38%-369M | 100.85%25M | 33.03%3.69B | 83.56%-408M | 172.85%1.26B | 91.23%-2.96B | 115.27%2.77B | 79.30%-2.48B |
| Minority profit | -1.80%1.69B | 8.51%701M | -24.40%378M | 51.65%1.79B | 18.62%1.72B | 63.13%646M | 187.36%500M | 216.32%1.18B | 364.60%1.45B | 179.84%396M |
| Profit attributable to shareholders | 17.40%2.31B | -45.54%-1.53B | -198.81%-747M | 57.27%-1.77B | 48.86%1.97B | 63.36%-1.05B | 139.83%756M | 87.34%-4.14B | 107.51%1.32B | 74.96%-2.88B |
| Basic earnings per share | 18.18%0.13 | -33.33%-0.08 | -200.00%-0.04 | 56.52%-0.1 | 57.14%0.11 | 62.50%-0.06 | 140.00%0.04 | 87.89%-0.23 | 106.80%0.07 | 76.47%-0.16 |
| Diluted earnings per share | 9.09%0.12 | -33.33%-0.08 | -225.00%-0.05 | 56.52%-0.1 | 120.00%0.11 | 62.50%-0.06 | 140.00%0.04 | 87.89%-0.23 | 104.85%0.05 | 76.47%-0.16 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS | CAS (2007) | IAS |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | Unqualified Opinion | -- | -- |
| Auditor | -- | -- | -- | KPMG Huazhen (Special General Partnership), KPMG | -- | -- | -- | KPMG Huazhen (Special General Partnership), KPMG | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.